Characteristics | DRE/TRUS n (%) | mpMRI n (%) | p value |
---|---|---|---|
T-category | |||
T1–T2a | 239 (87.2) | 67 (24.5) | <0.001 |
T2b–T2c | 30 (11.0) | 157 (57.3) | |
T3–T4 | 5 (1.8) | 50 (18.2) | |
Risk group | |||
Low-risk (LR) | 95 (34.7) | 32 (11.7) | <0.001 |
Intermediate-risk (IR) | 127 (46.4) | 163 (59.5) | |
High-risk (HR) | 52 (19.0) | 79 (28.8) | |
Target volume | |||
VVSS prophylactic | 174 (63.5) | 192 (70.1) | <0.001 |
T3a + T3b + T4 | 5 (1.8) | 50 (18.2) | |
Doses | |||
Low | 95 (34.7) | 32 (11.7) | <0.001 |
High | 179 (65.3) | 242 (88.3) | |
Hormonal therapy | |||
HR and IR (Initial criteria)a | |||
No | 182 (66.4) | 158 (57.7) | 0.035 |
Yes | 92 (33.6) | 116 (42.3) | |
HR and IR (MSKCC criteria)b | |||
No | 149 (54.4) | 103 (37.6) | <0.001 |
Yes | 125 (45.6) | 171 (62.4) | |
Hormonal therapy in IR patients | |||
Initial criteria | |||
No | 220 (80.3) | 221 (80.7) | 0.914 |
Yes | 54 (19.7) | 53 (19.3) | |
MSKCC criteria | 0.002 | ||
No | 180 (65.7) | 144 (52.6) | |
Yes | 94 (34.3) | 130 (47.4) | |
Hormonal therapy in HR patients | |||
No | 222 (81.0) | 195 (71.2) | 0.007 |
Yes | 52 (19.0) | 79 (28.8) |